About 150 S&P 500 companies are scheduled to release results this week, in an earnings season that has been mediocre.» Read More
In a down economy, investors often turn to Consumer Staples that are more insulated from economic cycles. Key in this sector are food stocks; after all we still have to eat. Yesterday, Conagra beat analyst expectations and today Erin Burnett interviews Kendall Powell, the CEO from General Mills. Here is a list of some of the biggest food related companies and how they have performed YTD.
Cramer makes the call on viewers' favorite stocks.
As markets edge higher in early morning trading, CNBC asked the experts how to leverage your portfolio.
Investors now think that a biotech company with less than one-third the revenue of Amgen is worth more than the former sector king. Elizabeth Trotta at TheStreet.com took note of this late last week but I thought it was worth pointing out.
How are American food producers coping with soaring commodity prices? Easy, says Wachovia Securities analyst Jonathan Feeney: They're passing along the prices to the consumer. That puts some major food producers and their stocks in a pretty good position.
Stocks declined Wednesday amid profit-taking from the prior session's rally, a sharp drop in crude prices and lingering concerns about credit.
Q: On Fast Money’s trader radar we look at the stock that was lighting up screens across Wall Street. Providing breakfast to champions since 1866 this company’s Betty Crocker products may leave you looking like the Pillsbury dough boy. On Wednesday investors thanked their “Lucky Charms” that booming sales of Yoplait yogurt and Fiber One cereal outweighed higher wheat costs. Who is it?
An early rally fizzled Wednesday amid profit-taking from the prior session's rally and lingering concerns about credit.
Stocks turned mixed Wednesday after an initial jump spurred by news that regulators will provide some much-needed capital relief to Fannie Mae and Freddie Mac. Visa shares surged.
There are reports this morning that Fannie Mae has won the capital relief some have asked for. At 9 am OFHEO (Office of Federal Housing Enterprise Oversight--Fannie's regulator) has scheduled a conference call to discuss alleviating some of the capital constraints on Fannie and Freddie.
General Mills on Wednesday posted higher quarterly profit as cost-cutting measures and higher sales helped offset soaring prices for wheat and other commodities.
The Federal Reserve cut the fed funds rate by three-quarters of a point, to 2.25 percent. CNBC asked the experts how investors should adjust their portfolios. Here's what they said.
What's on the menu for your portfolio? Morningstar equity analyst Mitchell Corwin has pinpointed five food-producing "standouts" with stocks at reasonable prices.
This could be the sector to own by next fall's presidential election.
In the week ahead, traders say the dysfunction in credit markets will continue to dominate, and they expect the stock market to keep testing lows in choppy trading.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
A tumbling US dollar and surging oil prices are bad news for consumers. But for smart investors, there are opportunities to profit.
The largest increase in wholesale inflation in 26 years has left many investors wondering how to protect their portfolios. CNBC asked the market pros what they would do.
Sarat Sethi thinks investors should feed their portfolios food stocks. "We're putting money into food stocks, which are necessities, not discretionary items," the partner and portfolio manager for Douglas C. Lane and Associates told CNBC.
The world's biggest drug company is spending chump change to take out a little biotech at a 118 percent premium. Pfizer, which has a cash hoard of more than $20 billion, is plunking down a paltry (for Pfizer, that is) $195 million in cash money to buy Encysive Pharmaceuticals.